Gamma camera developer ParkMedical Systems has filed a 510(k) application with the Food andDrug Administration for Isocam 2, the company's dual-head digitalcamera. Park filed the application in February, according to thecompany. Isocam 2 will be the
Gamma camera developer ParkMedical Systems has filed a 510(k) application with the Food andDrug Administration for Isocam 2, the company's dual-head digitalcamera. Park filed the application in February, according to thecompany.
Isocam 2 will be the second in Park's line of digital gammacameras.
Toronto-based Park began deliveries of a single-head versionof Isocam this year. The Isocam systems convert analog signalsto digital within individual photomultiplier tubes (SCAN 2/16/94and 4/7/93).
Isocam 2 will be a double threat to other gamma camera makers.Not only is the system digital, but the detector heads are adjustableto the 90º position for cardiac studies, according to thecompany. Isocam 2 will thus go head-to-head with Genesys Vertexfrom ADAC Laboratories and Sopha Medical's Sophycamera DST inthe adjustable dual-head segment.
In addition to its adjustable dual detectors, Isocam 2 canconduct 90º cardiac studies without moving the patient bedup and down, the company said. The camera's gantry is mountedon rails, allowing the camera to do a whole-body study in onepass.
Park Medical Systems, the principal subsidiary of Park Meditech,recently unified its corporate structure, absorbing several relatednuclear medicine companies and discontinuing the Isis name usedby the company that handled development of the Isocam line.
Park Meditech raised $9 million last month in a private placementoffering of 2.57 million special warrants, exchangeable for oneshare of common stock in the company and half of a common sharepurchase warrant. The cash will help ensure that Park MedicalSystems is adequately funded as the pace of Isocam productionand marketing picks up.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.